|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
SCIDIR_on1302132720 |
| 003 |
OCoLC |
| 005 |
20231120010635.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
220306s2022 enk o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d EBLCP
|d OCLCO
|d OCLCF
|d OCLCO
|d SFB
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1302105260
|a 1302177529
|
| 020 |
|
|
|a 9780128236871
|q (electronic bk.)
|
| 020 |
|
|
|a 0128236876
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128236864
|
| 020 |
|
|
|z 0128236868
|
| 035 |
|
|
|a (OCoLC)1302132720
|z (OCoLC)1302105260
|z (OCoLC)1302177529
|
| 050 |
|
4 |
|a RC271.I45
|
| 082 |
0 |
4 |
|a 616.99406
|2 23
|
| 245 |
0 |
0 |
|a Nanotherapeutics in cancer vaccination and challenges /
|c edited by Mahfoozur Rahman [and more].
|
| 260 |
|
|
|a London :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource
|
| 505 |
0 |
|
|a Front Cover -- Nanotherapeutics in Cancer Vaccination and Challenges -- Nanotherapeutics in Cancer Vaccination and Challenges -- Copyright -- Dedication -- Contents -- List of contributors -- Preface -- Acknowledgments -- 1 -- Cancer vaccines: past, present, and future -- 1. Introduction -- 2. Cancer vaccines and their applications -- 3. Smart carriers in cancer vaccine delivery -- 3.1 Nanoparticles -- 3.2 Liposomes -- 3.3 Nanoemulsions -- 3.4 Magnetic nanoparticles -- 3.5 Niosomes -- 3.6 Bilosomes -- 3.7 Archeosomes -- 3.8 Microspheres -- 3.9 Viral nanovectors
|
| 505 |
8 |
|
|a 3.10 Immuno potentiating virosomal carriers -- 4. Key challenges: formulation challenges and regulatory hurdles -- 5. Conclusion and future perspectives -- References -- 2 -- Inorganic nanoparticulate carriers in management of cancer: theranostics and toxicity apprehension -- 1. Introduction -- 2. Inorganic nanoparticles -- 2.1 QD -- 2.2 Gold nanoparticles -- 2.3 Magnetic nanoparticles -- 2.4 Mesoporous silica nanoparticles (MSNPs) -- 2.5 Aluminum-based nanoparticle -- 2.6 Calcium-based nanoparticle -- 2.7 Carbon nanoparticle -- 3. Advantages of inorganic nanoparticle
|
| 505 |
8 |
|
|a 4. Application of inorganic nanoparticles in cancer treatment -- 4.1 Toxicity -- 5. Conclusion -- References -- 3 -- Recent developments in cancer vaccines: where are we? -- 1. Introduction -- 2. Vaccines and their mechanism of action -- 3. Classification of cancer vaccine -- 3.1 Prophylactic vaccine -- 3.2 Autologous tumor cell vaccine -- 3.3 Allogenic tumor cell vaccine -- 3.4 Dendritic cell (DC) vaccine -- 3.5 Protein/peptide-based vaccine -- 3.6 Genetic vaccine -- 3.6.1 DNA vaccine -- 3.7 RNA vaccine -- 4. The fundamental mechanism of antitumor immunity -- 5. Cancer and its types
|
| 505 |
8 |
|
|a 5.1 Breast cancer -- 5.2 Liver cancer -- 5.3 Lung cancer -- 5.4 Bladder cancer -- 5.5 Colorectal cancer -- 5.6 Leukemia -- 5.7 Prostate cancer -- 5.8 Pancreatic cancer -- 5.9 Melanoma -- 5.10 Kidney cancer -- 6. Present cancer treatments -- 6.1 Surgery -- 6.2 Radiation therapy -- 6.3 Chemotherapy -- 6.4 Targeted therapy -- 6.4.1 Immunotherapy -- 6.5 Hormone therapy -- 6.6 Stem cell therapy -- 7. Significance of the development of cancer vaccine -- 8. Known or possible targets for the development of cancer vaccines -- 9. Current status on the development of cancer vaccines
|
| 505 |
8 |
|
|a 9.1 Preclinical studies on vaccine developments -- 9.2 Clinical studies on vaccine developments -- 10. Future perspectives of cancer vaccines -- 11. Conclusion -- 12. Conflict of interest -- Acknowledgments -- References -- 4 -- Application of nanotechnology assisted devices in cancer treatment -- 1. Introduction -- 2. Nanotechnology in cancer -- 3. Devices based on nanotechnology -- 4. Nanotechnology and medical devices -- 5. Emerging medical devices using nanotechnology for cancer therapy -- 6. Challenges and regulations -- 7. Advantages and disadvantages of nanotechnology in cancer
|
| 650 |
|
0 |
|a Cancer
|x Vaccination.
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
|
0 |
|a Cancer vaccines.
|
| 650 |
|
0 |
|a Nanoparticles.
|
| 650 |
|
2 |
|a Cancer Vaccines
|0 (DNLM)D019496
|
| 650 |
|
2 |
|a Nanoparticles
|0 (DNLM)D053758
|
| 650 |
|
2 |
|a Neoplasms
|x therapy
|0 (DNLM)D009369Q000628
|
| 650 |
|
2 |
|a Nanomedicine
|0 (DNLM)D050997
|
| 650 |
|
6 |
|a Cancer
|0 (CaQQLa)201-0004683
|x Vaccination.
|0 (CaQQLa)201-0380202
|
| 650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
| 650 |
|
6 |
|a Vaccins anticanc�ereux.
|0 (CaQQLa)201-0358889
|
| 650 |
|
6 |
|a Nanoparticules.
|0 (CaQQLa)201-0262530
|
| 650 |
|
7 |
|a Cancer
|x Vaccination
|2 fast
|0 (OCoLC)fst00845559
|
| 650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
| 700 |
1 |
|
|a Rahman, Mahfoozur.
|
| 776 |
0 |
8 |
|i ebook version :
|z 9780128236871
|
| 776 |
0 |
8 |
|c Original
|z 0128236868
|z 9780128236864
|w (OCoLC)1264458472
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128236864
|z Texto completo
|
